Turner Helen E, Harris Adrian L, Melmed Shlomo, Wass John A H
Department of Endocrinology, Churchill Hospital, Oxford OX3 7LJ, United Kingdom.
Endocr Rev. 2003 Oct;24(5):600-32. doi: 10.1210/er.2002-0008.
Angiogenesis is the process of new blood vessel development from preexisting vasculature. Although vascular endothelium is usually quiescent in the adult, active angiogenesis has been shown to be an important process for new vessel formation, tumor growth, progression, and spread. The angiogenic phenotype depends on the balance of proangiogenic growth factors such as vascular endothelial growth factor (VEGF) and inhibitors, as well as interactions with the extracellular matrix, allowing for endothelial migration. Endocrine glands are typically vascular organs, and their blood supply is essential for normal function and tight control of hormone feedback loops. In addition to metabolic factors such as hypoxia, the process of angiogenesis is also regulated by hormonal changes such as increased estrogen, IGF-I, and TSH levels. By measuring microvascular density, differences in angiogenesis have been related to differences in tumor behavior, and similar techniques have been applied to both benign and malignant endocrine tumors with the aim of identification of tumors that subsequently behave in an aggressive fashion. In contrast to other tumor types, pituitary tumors are less vascular than normal pituitary tissue, although the mechanism for this observation is not known. A relationship between angiogenesis and tumor size, tumor invasiveness, and aggressiveness has been shown in some pituitary tumor types, but not in others. There are few reports on the role of microvascular density or angiogenic factors in adrenal tumors. The mechanism of the vascular tumors, which include adrenomedullary tumors, found in patients with Von Hippel Lindau disease has been well characterized, and clinical trials of antiangiogenic therapy are currently being performed in patients with Von Hippel Lindau disease. Thyroid tumors are more vascular than normal thyroid tissue, and there is a clear correlation between increased VEGF expression and more aggressive thyroid tumor behavior and metastasis. Although parathyroid tissue induces angiogenesis when autotransplanted and PTH regulates both VEGF and MMP expression, there are few studies of angiogenesis and angiogenic factors in parathyroid tumors. An understanding of the balance of angiogenesis in these vascular tumors and mechanisms of vascular control may assist in therapeutic decisions and allow appropriately targeted treatment.
血管生成是指从已有的脉管系统发育出新血管的过程。尽管在成年人中血管内皮通常处于静止状态,但活跃的血管生成已被证明是新血管形成、肿瘤生长、进展和扩散的重要过程。血管生成表型取决于促血管生成生长因子(如血管内皮生长因子,VEGF)与抑制剂之间的平衡,以及与细胞外基质的相互作用,从而使内皮细胞得以迁移。内分泌腺通常是血管丰富的器官,其血液供应对于正常功能以及激素反馈回路的严格调控至关重要。除了诸如缺氧等代谢因素外,血管生成过程还受到激素变化的调节,如雌激素、胰岛素样生长因子 -I(IGF-I)和促甲状腺激素(TSH)水平升高。通过测量微血管密度,血管生成的差异已与肿瘤行为的差异相关联,类似技术已应用于良性和恶性内分泌肿瘤,目的是识别那些随后表现出侵袭性的肿瘤。与其他肿瘤类型不同,垂体瘤的血管比正常垂体组织少,尽管这一观察结果的机制尚不清楚。在某些类型的垂体瘤中已显示血管生成与肿瘤大小、肿瘤侵袭性和侵袭性之间存在关联,但在其他类型中则未发现。关于微血管密度或血管生成因子在肾上腺肿瘤中的作用的报道很少。在患有冯·希佩尔 - 林道病的患者中发现的血管肿瘤(包括肾上腺髓质肿瘤)的机制已得到充分阐明,目前正在对患有冯·希佩尔 - 林道病的患者进行抗血管生成治疗的临床试验。甲状腺肿瘤的血管比正常甲状腺组织丰富,VEGF表达增加与更具侵袭性的甲状腺肿瘤行为和转移之间存在明显相关性。尽管甲状旁腺组织自体移植时会诱导血管生成,且甲状旁腺激素(PTH)调节VEGF和基质金属蛋白酶(MMP)的表达,但关于甲状旁腺肿瘤中血管生成和血管生成因子的研究很少。了解这些血管肿瘤中血管生成的平衡以及血管控制机制可能有助于治疗决策并实现适当的靶向治疗。